TNF Pharmaceuticals, Inc. is a clinical-stage biotech company focused on developing immunometabolic and cannabinoid-based therapies targeting aging, autoimmune, and neurological diseases.

# Company Summary: TNF Pharmaceuticals, Inc.

## Overview
TNF Pharmaceuticals, Inc. (formerly MyMD Pharmaceuticals, Inc.) is a Delaware-incorporated clinical-stage pharmaceutical company focused on extending healthy lifespan through the development of novel immunometabolic and cannabinoid-based therapies.

## Core Focus
- **Therapeutic Platforms:** Based on two well-defined targets:
  - **Isomyosamine:** A small molecule drug aimed at regulating the immune system by inhibiting pro-inflammatory cytokines such as TNF-α, IL-6, and IL-17. It is developed to treat autoimmune diseases (e.g., rheumatoid arthritis, multiple sclerosis), age-related conditions like sarcopenia and frailty, and potentially other inflammatory and age-related disorders.
  - **Supera-CBD:** A synthetic analog of natural cannabidiol (CBD) developed for conditions like pain, anxiety, depression, epilepsy, and sleep disorders. It inhibits key receptors and enzymes, such as CB2, opioid receptors, and MAO-B, with potential applications in addiction, neuropsychiatric disorders, and other neurological conditions.

## Recent Corporate and Regulatory Changes
- Changed name from **MyMD Pharmaceuticals, Inc.** to **TNF Pharmaceuticals, Inc.** on July 22, 2024.
- Reincorporated in Delaware (effective March 4, 2024) from New Jersey.
- Conducted a 1-for-30 reverse stock split on February 14, 2024.
- Increased authorized shares of common stock from 16.7 million to 250 million on July 25, 2024.
- Publicly traded on Nasdaq under the ticker **"TNFA"** since July 24, 2024.

## Employees
- As of December 31, 2024: **2 full-time employees**.
- No part-time employees; no union relationships.

## Financials & Market Capitalization
- **Market Value (June 30, 2024):** Approximately **$3.788 million** (based on a stock price of $1.84).
- **Shares Outstanding (as of April 4, 2025):** **10,132,619** shares of common stock.
- **Financial Condition:** Incurs ongoing losses; in 2024, net loss of approximately **$27.16 million**; accumulated deficit of **$129.08 million** as of December 31, 2024.
- **Cash & Marketable Securities (as of December 31, 2024):** Approximately **$8.5 million**.

## Business Operations
- Focuses on developing and commercializing drugs targeting aging, autoimmune, and neurological diseases.
- No current revenue from product sales.
- Strategy involves progressing through clinical trials, regulatory approval, and potential commercialization.
- Clinical pipeline includes multiple Phase 1 and Phase 2 trials, notably for Isomyosamine in treatment of sarcopenia, rheumatoid arthritis, and autoimmune thyroiditis.

## Intellectual Property
- Holds **18 U.S. patents** and **69 foreign patents**; patent rights expected to expire between 2036-2041.
- Patents cover autoimmune diseases, age reversal, TNF-α reduction, addiction, and hair growth.
- Continuously prosecuting and protecting intellectual property rights.

## Key Development & Clinical Trial Plans
- Planning Phase 2b clinical trial for Isomyosamine in sarcopenia in early 2025.
- Conducting preclinical studies on Supera-CBD.
- Active IND (Investigational New Drug) applications, including for autoimmune diseases and Hashimoto’s Thyroiditis.
- No current regulatory approvals for any product candidate.

## Additional Details
- Operates in a highly competitive environment with significant emphasis on intellectual property.
- Relies on third-party manufacturers and CROs for clinical testing and manufacturing.
- No customer base or revenue mentioned; the company is in the development stage with ongoing clinical trials and regulatory processes.

MyMD Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing innovative therapies to extend healthy lifespan, focusing on conditions like autoimmune diseases and age-related illnesses.

# MyMD Overview

## Company Profile
**MyMD Pharmaceuticals, Inc.** is a clinical-stage pharmaceutical company focused on extending healthy lifespan by developing and commercializing innovative therapeutic platforms. The company has two main product candidates: **MYMD-1** and **Supera-CBD**.

## Therapeutic Platforms

### 1. MYMD-1
- **Type:** Clinical-stage small molecule
- **Mechanism of Action:** Regulates the immunometabolic system to treat autoimmune diseases and age-related illnesses by inhibiting the release of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-17.
- **Indications:**
  - Autoimmune diseases (e.g., rheumatoid arthritis, inflammatory bowel disease)
  - Age-related illnesses (e.g., frailty, sarcopenia)
- **Current Development Status:**
  - Completed Phase 1 trial in early 2020.
  - Completed Phase 2 trial for sarcopenia in June 2023, with a clinical safety report underway.
  - Active IND for multiple autoimmune diseases.
  - Planned advancement into Phase 2 clinical trials for rheumatoid arthritis and Hashimoto’s Thyroiditis.

### 2. Supera-CBD
- **Type:** Synthetic analog of Cannabidiol (CBD)
- **Mechanism of Action:** Targets multiple receptors, including the CB2 receptor and opioid receptors, and inhibits MAO-B to address conditions such as pain, anxiety, depression, and epilepsy.
- **Development Status:**
  - In early-stage development targeting epilepsy, addiction, and anxiety disorders.
  - IND-enabling studies are being planned.

## Company Statistics
- **Employees:** 6 full-time employees
- **Revenue:** The company currently generates no revenue from product sales as it is in the clinical stage.
- **Income:** Experienced net losses of **$8.2 million** for the year ended December 31, 2023, and **$15.2 million** for 2022. Total accumulated deficit stands at approximately **$101.98 million** as of December 31, 2023.
  
## Corporate History
- **Founded:** November 2014 as MyMD Florida.
- **Reincorporation:** Transitioned from New Jersey to Delaware in March 2024.
- **Merger:** Completed a merger with Akers Biosciences, Inc. in April 2021.
  
## Development Strategy
MyMD aims to:
- Extend healthy lifespan through innovative drug platforms targeting well-defined therapeutic targets.
- Focus on completing ongoing clinical trials and obtaining regulatory approvals.
- Expand the company’s intellectual property portfolio and commercial rights for product candidates.

## Future Prospects
MyMD Pharmaceuticals, Inc. continues to work towards advancing its product candidates through clinical trials with a potential goal of commercialization pending regulatory approvals. The company faces significant challenges typical of clinical-stage biopharmaceutical companies, especially those involving drug development and regulatory processes.

TNF Pharmaceuticals, Inc.

10-K / April 11, 2025

10-K / April 1, 2024

10-K / April 11, 2025

Company Summary: TNF Pharmaceuticals, Inc.

Overview

Core Focus

Recent Corporate and Regulatory Changes

Employees

Financials & Market Capitalization

Business Operations

Intellectual Property

Key Development & Clinical Trial Plans

Additional Details